All In Biotech

Drug Trial Radar · NCT03911505

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years With Late-onset Pompe Disease

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

21

Actual

Start

Feb 13, 2020

Primary completion

Mar 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric subjects with Pompe disease, aged 0 to \< 18 years

Conditions

  • Pompe Disease (Late-onset)

Interventions

  • Cipaglucosidase AlfaBiological

    Enzyme Replacement Therapy via intravenous infusion

  • MiglustatDrug

    Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat(AT2221)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) from baselineTime frame: 52 weeks

Locations

17 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Florida Clinical Research Center

    Gainesville, Florida

  • Wolfson Children's Hospital

    Jacksonville, Florida

  • Woodruff Memorial Research Building

    Atlanta, Georgia

  • St. Louis Children's Hospital

    St Louis, Missouri

  • Duke University Medical Center

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of Utah, Clinical and Translational Sciences Institute

    Salt Lake City, Utah

  • Lysosomal and Rare Disorders Research and Treatment Center, Inc.

    Fairfax, Virginia

  • Women's and Children's Hospital

    North Adelaide, South Australia, Australia

  • University of Calgary

    Calgary, Alberta, Canada

  • SphinCS GmbH Clinical Science for LSD

    Hochheim am Main, Hesse, Germany

  • San Gerardo Hospital

    Monza, Italy

  • Gunma University Hospital

    Gunma, Japan

  • Tohoku University Hospital

    Miyagi, Japan

  • Tokyo Women's Medical University

    Tokyo, Japan

  • Izumi City General Hospital

    Osaka, Izumi-Shi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.